Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03491215
Recruitment Status : Recruiting
First Posted : April 9, 2018
Last Update Posted : November 13, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The study is an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days to <18 years old with either grade II-IV aGvHD or grade II-IV SR-aGvHD. This trial will utilize age groups: Group 1 includes patients ≥12y to <18y, Group 2 includes patients ≥6y to <12y, Group 3 includes patients ≥2y to <6y, and Group 4 includes patients ≥28days to <2y.

Condition or disease Intervention/treatment Phase
Acute Graft Versus Host Disease Drug: Ruxolitinib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Actual Study Start Date : February 21, 2019
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : June 2, 2023


Arm Intervention/treatment
Experimental: Ruxolitinib
All patients will receive ruxolitinib in addition to corticosteroids +/-calcineurin inhibitor (CNI)
Drug: Ruxolitinib
Ruxolitinib taken orally (5mg tablets) or oral pediatric formulation and dosage based on age group
Other Name: INC424




Primary Outcome Measures :
  1. Measurement of pharmacokinetic (PK) parameter, AUC, in aGvHD and SR-aGvHD patients [ Time Frame: 28 days ]
    Phase I: Measurement will be using extensive PK sampling in Groups 1-3 and sparse sampling in Group 4

  2. Measurement of PK parameter, Cmax, in aGvHD and SR-aGvHD patients [ Time Frame: 28 days ]
    Phase I: Measurement will be using extensive PK sampling in Groups 1-3 and sparse sampling in Group 4.

  3. Measurement of PK parameter, T1/2, in aGvHD and SR-aGvHD patients [ Time Frame: 28 days ]
    Phase I: Measurement will be using extensive PK sampling in Groups 1-3 and sparse sampling in Group 4.

  4. Measurement of PK parameter, Ctrough, in aGvHD and SR-aGvHD patients [ Time Frame: 28 days ]
    Phase I: Measurement will use be using extensive PK sampling in Groups 1-3 and sparse sampling in Group 4.

  5. Age-based determination of RP2D for each of the groups 2-4 [ Time Frame: 28 days ]
    Phase I: Determination of RP2D for will be based on observed PK parameters.

  6. Overall response rate (ORR) [ Time Frame: 28 days ]
    Phase II: ORR is defined as the proportion of patients demonstrating a complete response (CR) or partial response (PR) without requirement for additional systemic therapies for an earlier progression, mixed response or non-response. Scoring of response will be relative to the organ stage at the start of the study treatment.


Secondary Outcome Measures :
  1. Percentage of all patients who achieve a CR or PR [ Time Frame: 56 Days ]
    To assess the rate of durable ORR at Day 56

  2. Percentage of patients who achieved OR (CR+PR) [ Time Frame: To estimate ORR at Day 14. ]
    14 days

  3. PK parameter: Area under the curve (AUC) versus safety [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamic relationship (comparison of AUC with safety)

  4. Duration of response (DOR) [ Time Frame: 48 weeks ]
    DOR is assessed for responders only and is defined as the time from first response until aGvHD progression or the date of additional systemic therapies for aGvHD. Onset of chronic GvHD, or death without prior observation of aGvHD progression are considered as competing risks.

  5. Weekly cumulative steroid dose for each patient [ Time Frame: up to 56 days ]
    To assess the cumulative steroid dose until Day 56

  6. Overall Survival (OS) [ Time Frame: 2 years ]
    OS is defined as the time from the start of treatment to the date of death due to any cause.

  7. Event-Free Survival (EFS) [ Time Frame: 2 years ]
    EFS is defined as the time from start of treatment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause.

  8. Failure-Free Survival (FFS) [ Time Frame: 2 years ]
    FFS is defined as the time from the start of treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment.

  9. Non Relapse Mortality (NRM) [ Time Frame: 2 years ]
    NRM is defined as the time from start of treatment to date of death not preceded by hematologic disease relapse/progression.

  10. Incidence of Malignancy Relapse/Progression (MR) [ Time Frame: 2 years ]
    MR is defined as the time from start of treatment to hematologic malignancy relapse/progression. Calculated for patients with underlying hematologic malignant disease.

  11. Incidence of cGvHD [ Time Frame: 2 years ]
    cGvHD is defined as the diagnosis of any cGvHD including mild, moderate, severe

  12. Monitoring of donor cell chimerism [ Time Frame: 2 years ]
    Monitoring of donor cell chimerism to assess graft failure is defined as initial whole blood or marrow donor chimerism >5% declining to <5% on subsequent measurements compared to baseline.

  13. Questionnaire on acceptability and palatability [ Time Frame: 24 weeks ]
    To describe the acceptability and palatability assessments of the ruxolitinib formulation for dose forms used after first dose, 1 month and 6 months.

  14. Percentage of all patients who achieve a complete response (CR) or partial response (PR) [ Time Frame: 56 days ]
    To assess the rate of durable ORR at Day 56

  15. PK parameter - maximum serum concentration (Cmax) versus efficacy [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamic relationship (comparison of Cmax with efficacy)

  16. PK parameter: Minimum serum concentration (Ctrough) versus safety [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamic relationships (comparison of Ctrough with safety)

  17. PK parameter: Cmax versus safety [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamics relationship (comparison of Cmax with safety)

  18. PK parameter: Ctrough versus efficacy [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamics relationship (comparison of Ctrough with efficacy)

  19. PK parameter: AUC versus efficacy [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamics relationship (comparison of AUC with efficacy)

  20. PK parameter: AUC versus PD biomarkers [ Time Frame: 24 weeks ]
    To assess pharmacokinetics/pharmacodynamics relationship (Comparison of AUC with PD biomarkers)

  21. PK parameter: Cmax versus PD biomarkers [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmocodynamic relationship (comparison of Cmax with PD biomarkers)

  22. PK parameter: Ctrough versus PD biomarkers [ Time Frame: 24 weeks ]
    To assess pharmacokinetic/pharmacodynamics relationship (Ctrough with PD biomarkers)

  23. Percentage of patients who achieved Overall Response (OR) [ Time Frame: Up to 28 days and before start of additional aGvHD therapy ]
    Estimation of Best overall response (BOR) - is defined as percentage of patients OR (complete response (CR) + partial response (PR)) at any time and up to Day 28 and before the start of additional systemic aGvHD therapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients age ≥28 days and <18 years at the time of informed consent.
  • Patients who have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of myeloablative or reduced intensity conditioning are eligible.
  • Patients with a clinically confirmed diagnosis of grades II-IV aGvHD within 48 hours prior to study treatment start. Patients may have either: Treatment-naïve aGvHD (criteria per Harris et al. 2016) OR Steroid refractory aGvHD as per institutional criteria, and the patient is currently receiving systemic corticosteroids.
  • Evident myeloid engraftment with ANC > 1,000/µl and platelet count >20,000/µl. (Use of growth factor supplementation and transfusion support is allowed.)

Exclusion Criteria:

  • Has received the following systemic therapy for aGvHD: a) Treatment-naïve aGvHD patients have received any prior systemic treatment of aGvHD except for a maximum 72h of prior systemic corticosteroid therapy of methylprednisolone or equivalent after the onset of acute GvHD. Patients are allowed to have received prior GvHD prophylaxis which is not counted as systemic treatment (as long as the prophylaxis was started prior to the diagnosis of aGvHD); OR b) SR-aGvHD patients have received two or more prior systemic treatments for aGvHD in addition to corticosteroids
  • Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome with both acute and chronic GvHD features (as defined by Jagasia et al 2015).
  • Failed prior alloSCT within the past 6 months.
  • Presence of relapsed primary malignancy, or who have been treated for relapse after the alloSCT was performed, or who may require rapid immune suppression withdrawal of immune suppression as pre-emergent treatment of early malignancy relapse.
  • Acute GvHD occurring after non-scheduled donor leukocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Note: Patients who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible.
  • Any corticosteroid therapy for indications other than aGvHD at doses > 1 mg/kg/day methylprednisolone (or equivalent prednisone dose 1.25 mg/kg/day) within 7 days of Screening. Routine corticosteroids administered during conditioning or cell infusion is allowed.
  • Patients who received JAK inhibitor therapy for any indication after initiation of current alloSCT conditioning.

Other protocol-defined Inclusion/Exclusion may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03491215


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +81337978748 novartis.email@novartis.com

Locations
Layout table for location information
Australia, Queensland
Novartis Investigative Site Recruiting
Brisbane, Queensland, Australia, 4101
Australia, Victoria
Novartis Investigative Site Recruiting
Parkville, Victoria, Australia, 3052
Belgium
Novartis Investigative Site Recruiting
Bruxelles, Belgium, 1200
Novartis Investigative Site Recruiting
Gent, Belgium, 9000
Novartis Investigative Site Recruiting
Leuven, Belgium, 3000
Novartis Investigative Site Recruiting
Liege, Belgium, 4000
Chile
Novartis Investigative Site Recruiting
Santiago, Chile, 664 0166
France
Novartis Investigative Site Recruiting
Lille, France, 59000
Novartis Investigative Site Recruiting
Rennes Cedex, France, 35022
Germany
Novartis Investigative Site Recruiting
Hamburg, Germany, 20246
Italy
Novartis Investigative Site Recruiting
Genova, GE, Italy, 16147
Novartis Investigative Site Recruiting
Roma, ITA, Italy, 00165
Japan
Novartis Investigative Site Recruiting
Nagoya, Aichi, Japan, 466 8560
Novartis Investigative Site Recruiting
Saitama, Japan, 330 8777
Slovenia
Novartis Investigative Site Recruiting
Ljubljana, Slovenia, 1000
Spain
Novartis Investigative Site Recruiting
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site Recruiting
Barcelona, Cataluña, Spain, 08025
Novartis Investigative Site Recruiting
Madrid, Spain, 28009
Novartis Investigative Site Recruiting
Madrid, Spain, 28046
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03491215     History of Changes
Other Study ID Numbers: CINC424F12201
2018-000422-55 ( EudraCT Number )
First Posted: April 9, 2018    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Graft versus host disease
GvHD
acute graft versus host disease
aGvHD
Steroid refractory acute graft versus host disease
SR-aGvHD
Ruxolitinib
INC424
allogeneic stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases